Evidence map›Paper›PMID 39951188›Full record

ArticleInternational journal of clinical oncology2025

Characteristics of patients with metastatic renal cell carcinoma who do not respond to axitinib treatment.

Kojiro Ohba, Takahiro Osawa, Takahiro Kojima, Tomohiko Hara, Mikio Sugimoto, Masatoshi Eto, Keita Minami, Yasutomo Nakai, Kosuke Ueda, Sei Naito and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kojiro OhbaDepartment of Urology and Renal Transplantation, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. ohba-k@nagasaki-u.ac.jp.ORCID http://orcid.org/0000-0003-2841-1998
Takahiro OsawaDepartment of Urology, Hokkaido University Hospital, Sapporo, Japan.
Takahiro KojimaDepartment of Urology, Aichi Cancer Center, Nagoya, Japan.
Tomohiko HaraOffice of Research Administration, Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Mikio SugimotoDepartment of Urology, Kagawa University, Kagawa, Japan.
Masatoshi EtoDepartment of Urology, Kyushu University, Fukuoka, Japan.
Keita MinamiDepartment of Urology, Sapporo City General Hospital, Sapporo, Japan.
Yasutomo NakaiDepartment of Urology, Osaka International Cancer Institute, Osaka, Japan.
Kosuke UedaDepartment of Urology, Kurume University Hospital, Kurume, Japan.
Sei NaitoDepartment of Urology, Yamagata University, Yamagata, Japan.
Norio NonomuraDepartment of Urology, Osaka University Hospital, Osaka, Japan.
Sachiyo MuraiDepartment of Urology, Hokkaido University Hospital, Sapporo, Japan.
Hiroyuki NishiyamaDepartment of Urology, University of Tsukuba Hospital, Tsukuba, Japan.
Hiromi NakanishiDepartment of Urology and Renal Transplantation, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Yuta MukaeDepartment of Urology and Renal Transplantation, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Kensuke MitsunariDepartment of Urology and Renal Transplantation, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Tomohiro MatsuoDepartment of Urology and Renal Transplantation, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Ryoichi ImamuraDepartment of Urology and Renal Transplantation, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Nobuo ShinoharaDepartment of Urology, Hokkaido University Hospital, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAxitinib is a widely used tyrosine kinase inhibitor (TKI) in metastatic renal cell carcinoma (mRCC) treatment. Here, we analyzed the characteristics of patients who did not respond to axitinib and evaluated alternative options for their treatment.

methodsWe retrospectively analyzed data for 449 patients with mRCC who were administered axitinib following another TKI as initial therapy. Patients with progressive disease (PD) at their first assessment were defined as showing early-PD. We analyzed the characteristics of patients at risk of early-PD and evaluated the relationship between the treatment following axitinib and their prognosis.

resultsEarly-PD was diagnosed in 102 patients, and was more common in those who had not undergone nephrectomy (p < 0.001), those treated with a TKI for a short period (p < 0.001), and those in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) poor risk category for mRCC (p < 0.001). Multivariate analysis showed that these were independent risk factors for early-PD (all p < 0.001). Of those with early-PD, 52 changed to next-line treatment. The progression-free survival periods were 5.5 (95% confidence interval (CI) 2.4-8.6) months for patients administered TKIs, 4.2 (95% CI 0.3-8.1) months for those on nivolumab, and 2.2 (1.8-2.6) months for those on mammalian target of rapamycin inhibitors (p = 0.030).

conclusionPatients who have not undergone nephrectomy, those previously treated with another TKI for a short period, and those in the IMDC poor risk category are more likely to experience early-PD when taking axitinib. Furthermore, TKIs are the best treatment for patients with early-PD who have previously been administered axitinib.

Indexed as

AxitinibCarcinoma, Renal CellKidney NeoplasmsProtein Kinase InhibitorsAdultAgedAged, 80 and overDisease ProgressionFemaleHumansMaleMiddle AgedNeoplasm MetastasisNephrectomyPrognosisProgression-Free SurvivalAxitinibProtein Kinase InhibitorsAxitinibDisease progressionMetastatic renal cell carcinomaNivolumabTyrosine kinase inhibitor

Identifiers

PMID39951188
PMCPMC11947068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.